Navigation Links
The Zacks Analyst Blog Highlights: SPDR Health Care Select Sector Fund, SPDR S&P 500, SPDRS&P Biotech ETF, PowerShares S&P SmallCap Health Care Portfolio and PowerShares Dynamic Biotechnology & Genome Portfolio

CHICAGO, Aug. 28, 2013 /PRNewswire/ -- announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include theSPDR Health Care Select Sector Fund (AMEX: XLV-Free Report), SPDR S&P 500 (AMEX: SPY-Free Report), SPDR S&P Biotech ETF (AMEX: XBI-Free Report), PowerShares S&P SmallCap Health Care Portfolio (Nasdaq: PSCH-Free Report) and PowerShares Dynamic Biotechnology & Genome Portfolio (AMEX: PBE-Free Report).


Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.

Here are highlights from Tuesday's Analyst Blog:

Play Surging Healthcare with These Small-Cap ETFs

The healthcare space has led the broad market for most of the first half of 2013 and continues its incredible run into the second half as well (read: Top ETFs of the First Half of the Year). In fact, the SPDR Health Care Select Sector Fund (AMEX: XLV-Free Report) is up nearly 24.9% in the year-to-date timeframe compared to 17.0% gains for SPDR S&P 500 (AMEX: SPY-Free Report).

This is largely thanks to some sector rotation along with strength in biotechnology and the pharmaceuticals firms. Investors of late have been moving out of lower risk, high dividend sectors like utilities and real estate investment trusts, into higher risk, growth sectors like financials, consumer discretionary and healthcare.

The healthcare space will likely be a bright spot going forward as the U.S. is one of the major markets for healthcare and one of the largest spenders on public health, putting the sector in an advantageous position.

The sector is poised to benefit from the aging population, higher rates of chronic disease, growing demand in emerging markets, product launches and increased mergers & acquisitions. Further, the sector also looks well positioned to profit from the imminent Affordable Care Act (also known as Obamacare) (read: 2 Great Healthcare ETFs in Focus).

Why Small Caps?

Investors are losing faith in the international economy with challenges to emerge from recession becoming tougher. Many emerging markets, including China, are also experiencing slowdown.

As a result, investors seeking to take real advantage of the growing healthcare space should focus in on small caps rather than the large caps. This is because small caps have more potential to move higher given their true domestic exposure (read: Time to Focus on Small Cap ETFs?).

These pint sized stocks aren't big enough to be international behemoths, so these focus mostly on the U.S. for their revenues, thereby promising returns in a global slowdown. Furthermore, given their small sizes, these have a much easier time growing than their already tapped out large cap counterparts.

While small caps are often capable of higher levels of growth than large caps, these can experience levels of volatility as huge gains and losses can occur in a very short period of time. In this backdrop, we have highlighted three small cap ETFs that have generated impressive returns so far this year.

Any of the following three could be rewarding for investors with a more domestic focus in the second half of the year (see more in the Zacks ETF Center).

SPDR S&P Biotech ETF (AMEX: XBI-Free Report)

This is by far the most popular choice in the biotech corner of the healthcare segment. The fund tracks the S&P Biotechnology Select Industry Index (read: Biotechnology ETF Investing 101). The product has $926.9 million in AUM and trades more than a quarter million in volume a day, while its cost is just 35 basis points a year.

XBI is an equal weighted ETF, spreading out assets across roughly 57 firms. No single company accounts for more than 2.93% of the portfolio. The fund allocates half of the assets in small cap securities while large cap takes just 14% share.

In terms of performance, the product generated more than 27% returns year-to-date and 21% in the trailing one-year period.

PowerShares S&P SmallCap Health Care Portfolio (Nasdaq: PSCH-Free Report)

This ETF tracks the S&P SmallCap 600 Capped Health Care Index and holds 66 securities in its basket. It is unpopular having amassed $119.6 million in asset base and trading in volume of less than 15,000 shares per day, while charging a relatively low 29 bps a year in fees.

From a securities look, the product is somewhat concentrated across each security as the top three holdings – Salix Pharmaceuticals, Cubist Pharmaceuticals and Centene Corp. – together make up for 14.5% share in the basket. PSCH is a small cap centric fund accounting for at least 85% of the assets.

Additionally, the fund is relatively well spread out from an industry perspective holding relatively equal portions of companies in the medical equipment, services, pharma, and biotech spaces. The ETF is up about 26.22% so far this year and 22.33% in the trailing one-year period.

PowerShares Dynamic Biotechnology & Genome Portfolio (AMEX: PBE-Free Report)

This ETF follows the Dynamic Biotechnology & Genome Intellidex Index. The product has a somewhat sparse volume of just 18,000 shares a day, but a decent level of assets under management of about $170 million. The fund charges 63 bps in fees and expenses from investors.

With holdings of 30 stocks, the fund is moderately concentrated in the top 10 holdings and focuses more on small caps with 41% of total assets. Large caps account for 23% while the rest goes towards mid caps. Waters Corp, Illumina and Life Technologies occupy the top three spots in the basket with a combined share of nearly 15%.

In terms of industrial exposure, 61% of assets are allocated to biotechnology while 29% are alloted pharmaceuticals (read: 3 Impressive Biotech ETFs Crushing the Market). The product has added an impressive 35% year-to-date and over 30% in the trailing one-year period.

Bottom Line

Although the near future of healthcare is uncertain as Obamacare fully gets underway, the long-term outlook looks promising. Health care will remain in demand no matter what happens, especially given the demographic shift in the U.S. and the insatiable demand for new treatments and drugs for a variety of illnesses.

Thus, these products could be an interesting choice for investors seeking higher returns from the space.

Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today.

About Zacks is a property of Zacks Investment Research, Inc., which was formed in 1978. The later formation of the Zacks Rank, a proprietary stock picking system; continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros.  In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros.


Get the full Report on XLV - FREE

Get the full Report on SPY - FREE

 Get the full Report on XBI - FREE

Get the full Report on PSCH - FREE

Get the full Report on PBE - FREE

Follow us on Twitter:

Join us on Facebook:

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.


Media Contact
Zacks Investment Research
800-767-3771 ext. 9339


Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit for information about the performance numbers displayed in this press release.




SOURCE Zacks Investment Research, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Zacks Investment Ideas feature highlights: Market Vectors Biotech ETF, iShares Nasdaq Biotechnology ETF, Regeneron, Celgene and First Trust Amex Biotechnology Index Fund
2. Sequenom to Host Analyst Day on Monday, November 14, 2011
3. Keryx Biopharmaceuticals Announces Live Webcast of Upcoming Analyst Day
4. Growing Awareness & Increasing Number of Indications Drive the Global Intravenous Immunoglobulin Market, According to a New Report by Global Industry Analysts, Inc.
5. Kitware to Improve Air Force Video Analyst Workflows with VIRAT
6. Environmental Concerns & Depleting Fossil Fuels Drive the Global Renewable Chemicals Market, According to New Report by Global Industry Analysts, Inc.
7. Global H1N1 Vaccines Market to Reach US $273 Million by 2018, According to a New Report by Global Industry Analysts, Inc.
8. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
9. Bayer HealthCares Cotavance® Drug Eluting Balloon With Paccocath® Technology Reduced Five-Year Target Lesion Revascularization Rates by 59 Percent in PAD Patients Compared to Those Treated With Uncoated Balloon
10. Organovo to Present at Lazard Capital Markets 8th Annual Healthcare Conference
11. Pharmasset to Present at the Lazard Capital Markets Healthcare Conference
Post Your Comments:
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... today announced the launch of the Supplyframe Design Lab . Located in ... to explore the future of how hardware projects are designed, built and brought ...
(Date:6/23/2016)... ... ... In a new case report published today in STEM CELLS Translational Medicine, ... after being treated for breast cancer benefitted from an injection of stem cells derived ... debilitating, frequent side effect of cancer treatment. , Lymphedema refers to the ...
(Date:6/23/2016)... 23, 2016  Blueprint Bio, a company dedicated to ... medical community, has closed its Series A funding round, ... "We have received a commitment from Forentis ... need to meet our current goals," stated Matthew ... runway to complete validation on the current projects in ...
(Date:6/23/2016)... June 23, 2016 On Wednesday, June ... 4,833.32, down 0.22%; the Dow Jones Industrial Average edged 0.27% ... at 2,085.45, down 0.17%. has initiated coverage on the ... Nektar Therapeutics (NASDAQ: NKTR ), Aralez Pharmaceuticals Inc. ... BIND ). Learn more about these stocks by ...
Breaking Biology Technology:
(Date:5/9/2016)... -- Elevay is currently known as the ... high net worth professionals seeking travel for work   ... there is still no substitute for a face-to-face meeting. ... deal with a firm handshake. This is why wealthy ... citizenship via investment programs like those offered by the ...
(Date:4/28/2016)... First quarter 2016:   , ... the first quarter of 2015 The gross margin was ... 18.8) and the operating margin was 40% (-13) Earnings ... flow from operations was SEK 249.9 M (21.2) , ... SEK 7,000-8,500 M. The operating margin for 2016 is ...
(Date:4/19/2016)... April 20, 2016 The new ... a compact web-based "all-in-one" system solution for all door ... reader or the door interface with integration authorization management ... control systems. The minimal dimensions of the access control ... the building installations offer considerable freedom of design with ...
Breaking Biology News(10 mins):